Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126


Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW.

Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8.


Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C, Urban N.

J Natl Cancer Inst. 2010 Jan 6;102(1):26-38. doi: 10.1093/jnci/djp438. Epub 2009 Dec 30.


B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.

Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW.

Cancer Res. 2006 Feb 1;66(3):1570-5.


B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.

Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP.

Gynecol Oncol. 2007 Aug;106(2):334-41. Epub 2007 May 11.


A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.

Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, Høyer-Hansen G, Borgfeldt C.

Anticancer Res. 2016 Mar;36(3):957-65.


Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.

Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, Davis G, Serra S, Diamandis EP, Kulasingam V.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.


Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.


Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.


Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.

Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R.

Int J Gynecol Cancer. 2010 Dec;20(9):1518-24.


A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.

Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U, Jacobs I, Graham RLJ.

Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.


Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.


Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.

Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, Moro R.

Tumour Biol. 2011 Aug;32(4):831-8. doi: 10.1007/s13277-011-0186-1. Epub 2011 May 28.


Comparison of candidate serologic markers for type I and type II ovarian cancer.

Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjær SK, Shih IeM, Roden RB.

Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24.


Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.

Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr.

Gynecol Oncol. 2011 Sep;122(3):548-53. doi: 10.1016/j.ygyno.2011.06.002. Epub 2011 Jun 25.


Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women.

Autelitano DJ, Raineri L, Knight K, Bannister K, Rice GE.

J Transl Med. 2012 Mar 12;10:45. doi: 10.1186/1479-5876-10-45.


Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.


Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Karabudak AA, Hafner J, Shetty V, Chen S, Secord AA, Morse MA, Philip R.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1757-70. doi: 10.1007/s00432-013-1501-6. Epub 2013 Sep 3.


CA125 and HE4: Measurement Tools for Ovarian Cancer.

Zhao T, Hu W.

Gynecol Obstet Invest. 2016;81(5):430-5. doi: 10.1159/000442288. Epub 2016 Apr 29.


B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W.

J Exp Med. 2006 Apr 17;203(4):871-81. Epub 2006 Apr 10.


Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.

Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS.

PLoS One. 2012;7(9):e44960. doi: 10.1371/journal.pone.0044960. Epub 2012 Sep 10.

Supplemental Content

Support Center